Kennondale Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Kennondale Capital Management’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Buy	+565,983	New	+$1.01M	0.77%	56

Other funds holding IKT

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Kennondale Capital Management's IKT Position: Q2 2026 in Review

Kennondale Capital Management opened a new position in Inhibikase Therapeutics (IKT) in Q2 2026: 565,983 shares worth $1.15M. The stake represents 0.77% of the portfolio and ranks #56 among its holdings.

40 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

Kennondale Capital Management held 565,983 shares of Inhibikase Therapeutics worth $1.15M as of Q2 2026.
Inhibikase Therapeutics was a new Kennondale Capital Management position in Q2 2026.
Inhibikase Therapeutics made up 0.77% of Kennondale Capital Management's portfolio in Q2 2026, its #56 holding.
40 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Kennondale Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.